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The innate capacity of adult somatic cells has many potential applications in regenerative medicine. In this
issue ofCell StemCell, Salero et al. (2012) describe an adult retinal stem cell population capable of generating
neural and mesenchymal cell lineages.Figure 1. VPR Is a Disease that Develops as a Result of a Tear in the Retina
Vitreous humor leaking into the retinal hole contains cytokines that activate the RPE. As a result, RPE
cells proliferate and migrate out into the vitreous compartment to form a fibrotic scar (image courtesy
of Dr. Philip J. Luthert, UCL). The findings from Salero, Blenkinsop and colleagues suggest that the
RPESC population could be the cell of origin for VPR.Age-related macular degeneration (AMD)
is the leading cause of blindness in people
over the age of 60 in the western world,
and each year the number of affected
people increases. AMD results in the
central portion of vision being lost, making
it impossible to appreciate fine detail.
About 25% of people over 60 in the UK
have some degree of visual loss due to
AMD and it is estimated that between 12
and 15 million people are affected by
this disease in the USA alone. AMD is
therefore a significant global healthcare
problem. In an exciting new paper in this
issue of Cell Stem Cell, Temple and
colleagues describe an adult stem cell
population in the retinal pigment epithelial
(RPE) cells that may provide a source of
cells for treating this disease (Salero
et al., 2012).
AMD is associated with defects of the
retinal support cells—the RPE cells. The
rods and cones (the photoreceptors) in
the retina, which are the light-sensitive
cells, depend on the RPE for their survival,
so RPE failure leads to progressive loss
of vision. To make matters worse, the
disease often provokes a scarring pro-
cess at the back of the eye, leading to
the formation of new blood vessels within
the retina (choroidal neovascularization,
CNV) that subsequently leak fluid, result-
ing in exudative AMD or so called ‘‘wet’’
AMD. The retina is very intolerant of this
scarring and rods and cones are lost
at a greater rate, leading to a more
dramatic loss of vision. This exudative
form of AMD occurs in 10% of AMD
patients, but is responsible for 90% of
cases of severe visual loss. AMD without
the neovascular component is referred
to as geographic atrophy or ‘‘dry’’ AMD.
Replacement of RPE cells (Coffey et al.,2002) or their translocation from the
peripheral retina is a viable treatment for
AMD, if surgical intervention occurs at
an appropriate time (da Cruz et al.,
2007). However, at present, availability
of suitable donor cells and the time
involved for the necessary complicated
retinal surgery means that these treat-
ments can only be made available to a
very small proportion of patients. Stem-
cell-based approaches therefore have
great therapeutic potential for presently
untreatable degenerative diseases such
as AMD.
In their paper, Salero, Blenkinsop, and
colleagues present important new data
demonstrating that the adult human RPE
contains a subpopulation of multipotent
RPE stem cells (RPESCs) that can be
activated to self-renew in vitro andCell Stem Celdifferentiate to give rise to neural and
mesenchymal progeny. Although RPE
cells do not proliferate in situ, these find-
ings suggest that RPESCsmay contribute
to repair or pathological differentiation
under conditions of injury and degenera-
tive disease.
To conduct their study, the authors ob-
tained eye samples from human donors
spanning a wide age range. They found
that RPE isolates grew robustly in
adherent conditions at similar growth
rates, independent of the age of the
donor, to produce confluent cobblestone
monolayers expressing RPE markers. A
fraction of the RPE cells self-renewed,
as demonstrated by their ability to form
spheres that could be serially propagated
and clonal analysis. Salero, Blenkinsop,
et al. next found that the cobblestonel 10, January 6, 2012 ª2012 Elsevier Inc. 1
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cell fate transitions. Growth in neural
differentiation medium caused the cells
to acquire an anterior/eye field progenitor
marker profile and suppress expression
of the RPE marker MITF. Surprisingly,
the authors also found that growth in
media promoting differentiation toward
mesenchymal lineages resulted in ex-
pression of markers consistent with
adipocyte, chondrocyte, and osteogenic
phenotypes. To rule out the possibility
that these cell types were generated
by contaminating mesenchymal cells
present in the starting culture, the authors
expanded clonal RPESC lines and con-
firmed that they were capable of gener-
ating RPE and mesenchymal progeny.
Furthermore, they found that GFP-labeled
human RPESCs could also give rise
to mesenchymal derivatives in a chick
chorioallantoic membrane assay.
Cellular plasticity in the RPE has been
regarded primarily as a property of lower
vertebrates (Araki, 2007). However, these2 Cell Stem Cell 10, January 6, 2012 ª2012 Enew findings suggest that adult human
RPESCs may hold the potential to
undergo complete transdifferentiation to
neuroretinal and other phenotypes. As
the authors discuss, an innate capacity
of the RPE to dedifferentiate in vivo
leads to a pathological condition called
proliferative vitreoretinopathy (PVR). PVR
occurs in the eye when the monolayer
of RPE is disrupted, typically by detach-
ment of the overlying neural retina. RPE
cells dislodge from their underlying
Bruch’s membrane and proliferate along
a mesenchymal lineage, resulting in a
fibroblastic scar (Figure 1). Salero and
colleagues were able to recapitulate
this phenomenon in vitro, providing an
important tool for identifying therapeutics
that can inhibit this process. Equally,
understanding how dedifferentiation and
expansion of RPE cells is regulated may
help in other diseases that involve RPE
degeneration.
Last but not least, these results provide
an important illustration of the reprogram-lsevier Inc.ming capacity of not just induced pluripo-
tent stem cells but even adult somatic
cells. Salero et al. convincingly show
that RPE cells maintain the ability in
adulthood to reprogram to become
multipotent along a mesenchymal lineage
and form precursors of a number of
different cell types. They therefore repre-
sent an additional source of adult human
stem cells.REFERENCES
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Similar to other highly self-renewing tissues, the intestinal epithelium contains both slowly and rapidly cycling
progenitor/stem cells, though their relationship has been largely unexplored. Two recent reports in Nature
(Tian et al., 2011) and Science (Takeda et al., 2011) shed new light on their dynamic interplay.The small intestinal epithelium has enor-
mous capacity for self-renewal, replacing
itself every 3 to 5 days. The cellular basis
for this regenerative potential has long
been accepted to reside in multipotent
intestinal stem cells (ISCs) (Cheng and
Leblond, 1974). Based on the hypothesis
that ISCs would be slowly cycling, Potten
and colleagues initially employed DNA
label retention models to identify these
cells. These studies led to the discovery
and characterization of putative ISCslocated in the ‘‘+4 crypt position’’ (Fig-
ure 1) (Potten et al., 1974). While this
finding subsequently gave rise to the dis-
covery of a number of additional markers
based on colocalization with label reten-
tion, functionally validated ISC markers
remained elusive for over three decades
(reviewed in Montgomery and Breault,
2008).
The first functionally validated ISC
marker to be identified was Lgr5, a
downstream target of canonical Wntsignaling (Barker et al., 2007). In contrast
to Potten’s original observation, Lgr5 ex-
pression corresponded to crypt base
columnar cells, located between Paneth
cells at the crypt base (Figure 1), a site
previously suggested to contain ISCs
(Bjerknes and Cheng, 1999). Surprisingly,
and in stark contrast to the label-retaining
population, the majority of Lgr5-express-
ing cells were shown to be rapidly cycling,
raising doubts as to whether bona fide
slowly cycling ISCs were also present in
